Emergency Use Authorization by FDA for Abbott’s BinaxNOW™ COVID-19 Ag Card Rapid Test
Emergence of COVID-19 resulted in development of several test and kits throughout the world. Few amongst them are Quantitative Polymerase Chain Reactions based tests, Real Time – Polymerase Chain Reactions based tests, Saliva Based Detection, Chest X- Ray etc.,
Towards their efforts in this endeavor, American based Medical Devices and Healthcare company, Abbott Laboratories has come-up with its Abbott’s BinaxNOW™ COVID-19 Ag Card Rapid Test. The BinaxNOW COVID-19 Ag Card helps in quantitative detection of unique COVID-19 antigens in human nasal cavity. As per the developers, the antigen testing is a reliable, fast and ease of use. On August 26, 2020 United States Food and Drug Administration has accorded the permission for EUA for the same. An important feature of BinaxNOW™ COVID-19 Ag Card is that it delivers the results with in 15 minutes with utmost accuracy. The test kit was priced at US$5, enables its affordability by common people as well.
In order to comprehend, the company is in the move to launch an application NAVICA™ that suits both for Android devices and iPhone which makes its practical utility on large scale. The commercial production of it is on the way.
